The effect of azithromycin in adults with stable neutrophilic COPD: A double blind randomised, placebo controlled trial

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Simpson, Jodie L ^a   Powell, Heather ^b   Baines, Katherine J ^a   Milne, David ^c   Coxson, Harvey O ^d   Hansbro, Philip M ^a   Gibson, Peter G ^a,b  

^a HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^b Hunter New England Area Health Service   (Australia)

^c AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; INTERLEUKIN 8; LEUKOCYTE ELASTASE; PLACEBO; ANTIINFECTIVE AGENT; IL8 PROTEIN, HUMAN;

ADD ON THERAPY; ADULT; ARTICLE; BACTERIAL COUNT; BACTERIAL LOAD; BACTERIUM ISOLATION; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; LEUKOCYTE DIFFERENTIAL COUNT; MALE; MIDDLE AGED; NEUTROPHIL COUNT; NEUTROPHILIC BRONCHITIS; NEUTROPHILIC CHRONIC OBSTRUCTIVE LUNG DISEASE; NONHUMAN; ONSET AGE; RANDOMIZED CONTROLLED TRIAL; SPUTUM ANALYSIS; TREATMENT DURATION; AGED; CLINICAL TRIAL; METABOLISM; MICROBIOLOGY; MULTICENTER STUDY; NEUTROPHIL; PATHOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-8; LEUKOCYTE ELASTASE; MALE; MIDDLE AGED; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM;

EID: 84921001401     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105609     Document Type: Article

References (38)

1. Simpson JL, Gibson PG, Yang IA, Upham J, James A, et al. (2013) Impaired macrophage phagocytosis in non-eosinophilic asthma. Clin Exp Allergy 43: 29-35.
2. Simpson JL, Phipps S, Gibson PG (2009) Inflammatory mechanisms and treatment of obstructive airway diseases with neutrophilic bronchitis. Pharmacology & Therapeutics 124: 86-95.
3. Wilkinson TMA, Patel IS, Wilks M, Donaldson GC, Wedzicha JA (2003) Airway Bacterial Load and FEV1 Decline in Patients with Chronic Obstructive Pulmonary Disease 10.1164/rccm.200210-1179OC. Am J Respir Crit Care Med 167: 1090-1095.
4. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA (2002) Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57: 847-852. (Pubitemid 35178607)
5. Simpson JL, McDonald VM, Baines KJ, Oreo KM, Wang F, et al. (2013) Influence of age, past smoking, and disease severity on TLR2, neutrophilic inflammation, and MMP-9 levels in COPD. Mediators Inflamm 2013: 462934.
6. Stanescu D, Sanna A, Veriter C, Kostianev S, Calcagni PG, et al. (1996) Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 51: 267-271. (Pubitemid 26086470)
7. Fujita K, Shimizu T, Majima Y, Sakakura Y (2000) Effects of macrolides on interleikin-8 secretion from human nasal epithelial cells. Eur Arch Otorhinolaryngol 257: 199-204. (Pubitemid 30259060)
8. Yamaryo T, Oishi K, Yoshimine H, Tsuchiashi Y, Matsushima K, et al. (2003) Fourteen-member macrolides promote the phosphatidylserine receptor-dependent phagocytosis of apoptotic neutrophils by alveolar macrophages. Antimicrob Agents Chemo 47: 48-53. (Pubitemid 36070341)
9. Wolter J, Seeney S, Bell S, Bowler S, Masel P, et al. (2002) Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 57: 212-216. (Pubitemid 34214405)
10. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG (2008) Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 177: 148-155.
11. Wong C, Jayaram L, Karalua N, Eaton T, Tong C, et al. (2012) Azithromycin for prevention of exacerbationsin non-cystic fibrosis bronchiectasis (EMBRACE): a randomised double-blind, placebo controlled trial. Lancet 380: 660-667.
12. Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, et al. (2013) Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomised controlled trial. JAMA 309: 1260-1267.
13. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Jr., et al. (2011) Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365: 689-698.
14. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS (2001) NHLBI/WHO Global initiative for chronic obstructive lung disease (GOLD) Workshp summary. Am J Respir Crit Care Med 163: 1256-1276.
15. Simpson JL, Scott R, Boyle MJ, Gibson PG (2006) Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 11: 54-61.
16. Jones PW, Quirk FH, Baveystock CM, Littlejohns P (1992) A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 145: 1321-1327.
17. van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, et al. (2003) Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 1: 13.
18. Ferris BD (1978) Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis 118: 1-120.
19. Sato S, Nishimura K, Koyama H, Tsukino M, Oga T, et al. (2003) Optimal cutoff levels of breath carbon monoxide for assessming smoking status of patients with asthma and COPD. Chest 124: 1749-1754. (Pubitemid 37433568)
20. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, et al. (2000) Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320: 1297-1303. (Pubitemid 30245717)
21. Knudson RJ, Slatin RC, Lebowitz MD, Burrows B (1976) The maximal expiratory flow-volume curve. Normal standards, variability, and effects of age. Am Rev Respir Dis 113: 587-600.
22. American Thoracic Society (1995) Single-breath Carbon Monoxide Diffusing Capacity (Transfer Factor). Am J Respir Crit Care Med 152: 2185-2198.
23. Simpson JL, Milne DG, Gibson PG (2009) Neutrophilic asthma has different radiographic features to COPD and smokers. Respir Med 103: 881-887.
24. Gibson PG, Wlodarczyk JW, Hensley MJ, Gleeson M, Henry RL, et al. (1998) Epidemiological association of airway inflammation with asthma symptoms and airway hyperresponsiveness in childhood. Am J Resp Crit Care Med 158: 36-41. (Pubitemid 28337155)
25. Charalambous BM, Batt SL, Peek AC, Mwerinde H, Sam N, et al. (2003) Quantitative validation of media for transportation and storage of Streptococcus pneumoniae. J Clin Microbiol 41: 5551-5556. (Pubitemid 37543244)
26. Baselski VS, Wunderink RG (1994) Bronchoscopic diagnosis of Pneumonia. Clinical Micro Reviews 7: 533-558. (Pubitemid 24317878)
27. Basyigit I, Yildiz F, Ozkara SK, Yildirim E, Boyaci H, et al. (2004) The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data. Ann Pharmacother 38: 1400-1405. (Pubitemid 39100191)
28. (2013) Global Strategy for the management and prevention of asthma 2013 (update).
29. Wilkinson TMA, Patel IS, Wilks M, Donaldson GC, Wedzicha JA (2003) Airway bacterial load and FEV1 decline in patient with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167: 1090-1095. (Pubitemid 36459654)
30. Yao GY, Ma YL, Zhang MQ, Gao ZC (2013) Macrolide Therapy Decreases Chronic Obstructive Pulmonary Disease Exacerbation: A Meta-Analysis. Respiration.
31. Kadota J, Mukae H, Mizunoe S, Kishi K, Tokimatsu I, et al. (2005) Long-term macrolide antibiotic therapy in the treatment of chronic small airway disease clinically mimicking diffuse panbronchiolitis. Intern Med 44: 200-206. (Pubitemid 40575898)
32. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE (2006) Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 174: 566-570. (Pubitemid 44330550)
33. Hansbro PM, Jarnicki AG (2012) Macrolides for macrophages in chronic obstructive pulmonary disease. Respirology 17: 739-740.
34. Banerjee D, Honeybourne D, Khair OA (2004) The effect of oral clarithromcin on bronchial airway inflammation in moderate to severe stable COPD. Treat Respir Med 3: 59-65. (Pubitemid 38444332)
35. He ZY, Ou LM, Zhang JQ, Bai J, Liu GN, et al. (2010) Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration 80: 445-452.
36. Seemungal TAR, Wilkinson TMA, Hurst JR, Perera WR, Sapsford RJ, et al. (2008) Long term erythromycin therapy is associated with decreased COPD exacerbations. Am J Respir Crit Care Med 178: 1139-1147.
37. Marjanovic N, Bosnar M, Michielin F, Wille DR, Anic-Milic T, et al. (2011) Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro. Pharmacol Res 63: 389-397.
38. Basyigit I, Yildiz F, Ozkara SK, Yildirim E, Boyaci H, et al. (2004) The effect of clarithromycin on inflammatory markers in Chronic Obstructive Pulmonary Disease: Preliminary Data. Ann Pharmacother 38: 1400-1405. (Pubitemid 39100191)